6 min read
Gastrointestinal Research Peptides
How BPC-157 and related compounds intestinal barrier function and inflammatory pathway modulation in preclinical models.
The Gut Barrier and Why It Breaks Down
The intestinal epithelium is a single-cell-thick barrier separating the gut lumen from the bloodstream. Tight junction proteins — claudins, occludins, and zonula occludens — hold these cells together. When tight junctions are compromised by inflammation, stress, NSAIDs, alcohol, or infection, intestinal permeability increases (commonly called "leaky gut"). This allows bacterial endotoxins, undigested food particles, and inflammatory mediators to enter the bloodstream, driving systemic inflammation.
BPC-157: The Body Protection Compound
BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from a protein found in human gastric juice. It is one of the most extensively studied peptides in gastrointestinal research. In animal models, BPC-157 has been associated with: effects on gastric ulcer models, restoration of tight junction protein expression, protection against NSAID-induced gut damage, and modulation of the nitric oxide (NO) system. BPC-157 appears to promote angiogenesis (new blood vessel formation) at injury sites in preclinical models.
The Nitric Oxide Connection
A key mechanism of BPC-157 involves the nitric oxide (NO) system. NO is a gaseous signalling molecule that regulates blood vessel dilation, blood flow, and inflammation. BPC-157 appears to interact with the NO system to maintain adequate blood supply to damaged tissue, counteracting the vasoconstriction that accompanies injury. This mechanism may explain its broad protective effects across multiple tissue types — gut, tendon, muscle, and even nerve tissue.
KPV: The Anti-Inflammatory Tripeptide
KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). Research indicates it inhibits NF-kB signalling — one of the central inflammatory pathways. In intestinal research models, KPV has been studied for effects on mucosal inflammation and epithelial barrier function. Some researchers investigate KPV alongside BPC-157, as the anti-inflammatory mechanism (KPV) is proposed to complement the tissue response mechanism (BPC-157) in preclinical models.
Research Protocol Considerations
BPC-157 is typically supplied as a lyophilised powder reconstituted with bacteriostatic water for research use. It is remarkably stable compared to most peptides — resistant to degradation in gastric juice (consistent with its origin). Storage at -20°C in lyophilised form preserves potency for 24–36 months. Once reconstituted, refrigerate and use within 42 days. For in vitro research use only.
Research Disclaimer: All content on this page is provided for educational and informational purposes only and relates strictly to published preclinical research. Silver Peptide products are supplied for in vitro laboratory research use only. They are not approved by the MHRA, FDA, or any regulatory body for human consumption, injection, or veterinary use. They are not medicines and must not be used as such. Nothing on this page constitutes medical advice.